CASI Pharmaceuticals Inc. (CASI, Financial) experienced a significant stock price drop of 6.33%, trading at $5.77 per share with a volume of 6,320 shares. This represents a turnover rate of 0.04% and amplitude of 0.98%.
Recent financial reports reveal that CASI Pharmaceuticals reported revenue of $3.98 million and a net loss of $6.97 million. The company posted an earnings per share of -$0.52, a gross profit of $2.07 million, and a price-to-earnings ratio of -2.93.
Among analysts, 100% of the participating institution rated CASI Pharmaceuticals a 'buy,' with no recommendations for hold or sell. In the broader biotechnology sector, the industry experienced a minor decline of 0.01%.
Other notable stocks in the sector include Cero Therapeutics Holdings Inc., Silexion Therapeutics Corp, and Lixte Biotechnology Holdings Inc., all showing considerable gains. Active stocks such as Aditxt, Inc., Silexion Therapeutics Corp, and Sagimet Biosciences Inc. had high turnover rates of 692.62%, 593.90%, and 126.46%, respectively. Stocks with significant price fluctuations included Tevogen Bio Holdings Inc., Nls Pharmaceutics Ltd, and Tc Biopharm (Holdings) Plc.
CASI Pharmaceuticals is a biopharmaceutical company focused on commercializing innovative therapies and drugs. Their product portfolio includes treatments for leukemia and lymphoma patients, such as EVOMELA for conditioning therapy prior to autologous stem cell transplantation in multiple myeloma patients. Key products are CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, and ENMD-2076. The majority of revenue comes from EVOMELA sales, with operations primarily in the USA, Canada, China, and other regions globally.
